Skip to main content

Advertisement

Figure 2 | BMC Cancer

Figure 2

From: Targeting of CD34+CD38-cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia

Figure 2

Phospho-chk2(thr68) in treated cells. Cells were treated with 10 ng/ml GO, 5 μM tipifarnib or the combination. Data are expressed as phospho-chk2 test – isotype control fluorescence intensity compared to untreated cells. (a) TF1A cells, n = 3, treated for 24 hours. (b) Flow cytometric histograms illustrating phospho-chk2 in bulk cells, CD34+CD38- and CD34+CD38+ subsets in a patient sample: dark histogram = untreated cells, pale histogram = cells treated with tipifarnib + GO. (c) Summary chart of phospho-chk2 in primary AML; n = 14 bulk, n = 12 CD34+CD38- and CD34+CD38+ subsets, treated for 48 hours. Median values are shown by a solid bar. * represents a P value compared with untreated cells of <0.05 and ** represents P < 0.01

Back to article page